State Board of Administration of Florida Retirement System trimmed its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating) by 10.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,467 shares of the company’s stock after selling 1,630 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Kiniksa Pharmaceuticals were worth $202,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in the company. AlphaCentric Advisors LLC lifted its stake in Kiniksa Pharmaceuticals by 4.7% during the fourth quarter. AlphaCentric Advisors LLC now owns 45,000 shares of the company’s stock worth $674,000 after purchasing an additional 2,000 shares in the last quarter. Jackson Creek Investment Advisors LLC purchased a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter worth $923,000. Strs Ohio purchased a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter worth $570,000. Allspring Global Investments Holdings LLC raised its stake in shares of Kiniksa Pharmaceuticals by 890.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 215,119 shares of the company’s stock valued at $3,222,000 after acquiring an additional 193,404 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its stake in shares of Kiniksa Pharmaceuticals by 14.5% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 79,419 shares of the company’s stock valued at $1,190,000 after acquiring an additional 10,041 shares in the last quarter. 42.98% of the stock is currently owned by institutional investors and hedge funds.
Kiniksa Pharmaceuticals Price Performance
Kiniksa Pharmaceuticals stock opened at $13.56 on Tuesday. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $7.36 and a 1-year high of $17.19. The stock has a market cap of $947.84 million, a PE ratio of 4.90 and a beta of -0.10. The stock’s fifty day moving average is $11.88 and its two-hundred day moving average is $13.63.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on KNSA. Wedbush reduced their price objective on Kiniksa Pharmaceuticals from $26.00 to $20.00 in a research note on Wednesday, March 1st. JPMorgan Chase & Co. increased their price objective on Kiniksa Pharmaceuticals from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Thursday, March 9th.
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404.
- Get a free copy of the StockNews.com research report on Kiniksa Pharmaceuticals (KNSA)
- monday.com Surges on Price and Volume after Blowout Results
- Can Ryanair Stock Fly Above Resistance Levels, What Earnings Show
- All Aboard! The Sell-Side Has Railroads In Reversal
- Is There Value Left in Lyft Stock?
- Everything About ZIM Integrated Screams Undervaluation
Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating).
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.